Zobrazeno 1 - 10 of 64 pro vyhledávání: '"J.R. Azanza Perea"'
1
Akademický článek
Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis
Autor: D.V. Pérez Civantos, M. Robles Marcos, J.R. Azanza Perea, C. Pazos Pacheco, F. García-Montoto Pérez, V. Jerez Gómez-Coronado
Publikováno v: International Journal of Infectious Diseases, Vol 86, Iss , Pp 142-146 (2019)
Objective: To describe the pharmacokinetic (PK) profile of anidulafungin and to evaluate its concentration in the peritoneal fluid (PF) of patients suspected of suffering from peritoneal infection undergoing abdominal surgery, in order to ensure that
Externí odkaz: https://doaj.org/article/7552281a68a4420392c07dcefbe03a3a
Zobrazit plný text záznamu
2
Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis
Autor: F. García-Montoto Pérez, C. Pazos Pacheco, J.R. Azanza Perea, D.V. Pérez Civantos, V. Jerez Gómez-Coronado, M. Robles Marcos
Publikováno v: Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
International Journal of Infectious Diseases, Vol 86, Iss, Pp 142-146 (2019)
Objective: To describe the pharmacokinetic (PK) profile of anidulafungin and to evaluate its concentration in the peritoneal fluid (PF) of patients suspected of suffering from peritoneal infection undergoing abdominal surgery, in order to ensure that
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11798824a4c93a4dafd3980372fd5f31
https://hdl.handle.net/10171/63624
Zobrazit plný text záznamu
3
Complicaciones gástricas de tratamientos farmacológicos
Autor: Isabel Gil-Aldea, J.R. Azanza Perea
Publikováno v: Medicine - Programa de Formación Médica Continuada Acreditado. 12:137-142
Resumen Introduccion Las complicaciones gastricas de los medicamentos constituyen unos de los efectos adversos mas destacados y de mayor relevancia clinica, siendo los AINE los principales causantes. Patogenesis El dano a nivel de la mucosa gastrica
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e19c72603df3cab7d6c97660fff5e01
https://doi.org/10.1016/j.med.2016.02.004
Zobrazit plný text záznamu
4
Bioavailability of two oral fentanyl transmucosal formulations in healthy volunteers: an open-label, crossover, randomised study
Autor: B. Sádaba-Díaz-de-Rada, B. Goñi-Allo, P. Nolasc-Roset-Arissó, A. Gómez-Guiu-Hormigós, J.R. Azanza-Perea
Publikováno v: Revista de la Sociedad Española del Dolor v.25 n.4 2018
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
espanolIntroduccion: El citrato de fentanilo oral transmucosa (CFOT) fue el primer medicamento disenado especificamente para tratar el dolor irruptivo. Esta formulado como una matriz de polvo comprimido con aplicador de plastico (palito), y el pacien
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8d49e45def1ffaef38c290c389207bc
https://hdl.handle.net/10171/64792
Zobrazit plný text záznamu
5
Aflibercept. Una aproximación a la farmacología
Autor: B. Sádaba, J.R. Azanza Perea
Publikováno v: Archivos de la Sociedad Española de Oftalmología. 90:6-10
Aflibercept is a fusion protein whose chemical structure combines the constant fraction of any IgG with a variable fraction constructed with fundamental parts of VEGF receptors. Consequently, it is able to bind to various VEGF as well as to placental
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5223b02161940ebb7e1d52ca9a74974d
https://doi.org/10.1016/s0365-6691(15)30003-4
Zobrazit plný text záznamu
6
Ranibizumab frente a bevacizumab. Consideraciones farmacológicas
Autor: A García Layana, J.R. Azanza Perea
Publikováno v: Archivos de la Sociedad Española de Oftalmología. 87:3-9
Bevacizumab is able to cross ocular barriers when administered through the intravitreal route and to generate plasma concentrations with an inhibitory effect on plasma vascular endothelial growth factor (VEGF). Consequently, systemic effects cannot b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::58dec4630b8eba122d553c5b14f43107
https://doi.org/10.1016/s0365-6691(12)70046-1
Zobrazit plný text záznamu
7
Oral versus intravenous therapy in the treatment of systemic mycosis
Autor: J.R. Azanza Perea, B Sádaba Díaz de Rada, E. Garcia Quetglas, M.J. Muñóz Juarez
Publikováno v: Clinical Microbiology and Infection. 10:96-106
The great majority of systemic fungal infections require long-term therapy that often extends 6–12 months, particularly in immunosuppressed patients. It can be difficult to comply with this requirement when the drug to be used is only available for
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97540b126ff323c73557d73b95e144b6
Zobrazit plný text záznamu
10
Bilastine for the relief of allergy symptoms
Autor: A. Gómez-Guiu Hormigos, J.R. Azanza Perea, B Sádaba Díaz de Rada
Publikováno v: Drugs of Today. 47:251
Bilastine is a potent inhibitor of the histamine H1 receptor. It was recently approved in 28 countries of the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria in adults and children older than 12 years. Data
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07fb0c52fa70e1b2a87671c520ff0253
https://doi.org/10.1358/dot.2011.47.4.1587029
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje